Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholesterol 7alpha-hydroxylase (CYP7A1) is a cytochrome P450 enzyme that catalyzes the rate-limiting step in bile acid synthesis. It is essential for cholesterol homeostasis and is a potential therapeutic target for hyperlipidemia, gallstone disease, and metabolic disorders. CYP7A1 expression is regulated by LXR and FXR, and genetic deficiencies can lead to hypercholesterolemia and increased risk of gallstones.
CYP7A1 catalyzes the first and rate-limiting step in the classic pathway of bile acid synthesis from cholesterol in the liver. It converts cholesterol to 7α-hydroxycholesterol, initiating its catabolism and facilitating cholesterol excretion via bile acids.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholesterol 7alpha-hydroxylase (CYP7A1).